Skip to main content
News

Managing IP Americas Awards 2024 Recognizes Arnold & Porter IP and Life Sciences Transactions Capabilities

April 26, 2024

Arnold & Porter was recognized in the following categories at the Managing IP Americas Awards honoring "remarkable achievements and developments in the last year."

  • National Firm of the Year - Patent Disputes
  • Impact Case of the Year - Amgen Inc. v. Sanofi
  • Impact Case of the Year - Hologic v. Minerva
  • DC Litigator of the Year - Matt Wolf
  • Impact Deal of the Year - Pfizer sale to Alexion and AstraZeneca

The firm's "National Firm of the Year" win in patent disputes follows decisive victories for clients that included Sanofi, Regeneron, and Hologic. In Amgen Inc. v. Sanofi, the firm achieved a significant victory at the U.S. Supreme Court for pharmaceutical companies Sanofi-Aventis US and Regeneron Pharmaceuticals Inc. in a closely watched biotechnology case related to the scope and validity of antibody patents and the proper enablement test. In Hologic v. Minerva, the firm secured a complete plaintiff and counter-claim defense jury verdict for Hologic and affirmance on appeal, and the U.S. Supreme Court upheld the assignor estoppel doctrine. The firm was also named "National Firm of the Year - Patent Disputes" by Managing IP in 2022.

The firm's wins in Amgen Inc. v. Sanofi and Hologic v. Minerva were also honored as two of the nine matters that Managing IP named "Impact Case of the Year." Partner Matt Wolf was named "DC Litigator of the Year" for leading the firm's victories in these two cases, as well as for his $158 million litigation win for Boston Scientific in a case that began in 2015.

Managing IP also recognized the Pfizer sale of its early-stage, rare disease gene therapy portfolio to Alexion and AstraZeneca for $1 billion as an "Impact Deal of the Year." The firm represented Pfizer in the transfer of Pfizer's novel adeno-associated virus (AAV) capsids, an innovative tool vital to transferring therapeutic genes to patients and will help build on Alexion and AstraZeneca's capabilities in genomic medicine. The Arnold & Porter team was led by co-head of the firm's Private Equity and Life Sciences Transactions practices Lowell Dashefsky and senior associate Tom Wilson.